Identification of Patients With Luminal Androgen Receptor TNBC

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses the identification of patients with luminal androgen receptor (LAR) triple-negative breast cancer (TNBC) during the 2018 San Antonio Breast Cancer Symposium.

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses the identification of patients with luminal androgen receptor (LAR) triple-negative breast cancer (TNBC) during the 2018 San Antonio Breast Cancer Symposium.

TNBC is best defined by what it does not have than what it has, Leon Ferre says. Ongoing research is looking at better classification schemes for patients with TNBC. In a study on the characteristics, outcomes, and prognostic factors of TNBC, Leon Ferre and his colleagues focused on the LAR subtype—–a subtype that is enriched for non-estrogen hormone signals. Some have posited that this subtype behaves differently than most TNBCs.